Related Experiment Video
Updated: Jun 4, 2025

06:13
Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
Published on: March 1, 2024
830
Thalamic deep brain stimulation for central poststroke pain syndrome: an international multicenter study
Andreas Nowacki1, David Y Zhang1, Can Sarica2
11Department of Neurosurgery, Inselspital, Bern University Hospital, University Bern, Switzerland.
Journal of Neurosurgery
|January 3, 2025
Summary
Deep brain stimulation (DBS) effectively treats central poststroke pain (CPSP) in some patients. Optimal stimulation sites include the internal capsule and sensorimotor thalamus, with connectivity patterns potentially predicting outcomes.
Area of Science:
- Neurology
- Neurosurgery
- Pain Medicine
Background:
- Central poststroke pain (CPSP) is a debilitating condition with limited treatment options.
- Deep brain stimulation (DBS) is a potential therapy for CPSP, but optimal targets and predictors of success are unclear.
Purpose of the Study:
- To evaluate the effectiveness and identify optimal stimulation sites for DBS in treating CPSP.
- To assess clinical and neuroimaging predictors of long-term outcomes in patients undergoing DBS for CPSP.
Main Methods:
- Retrospective analysis of international multicenter data from 6 DBS centers.
- Reconstruction and normalization of DBS leads, construction of stimulation maps.
- Projection of lesions and volumes of tissue activated (VTAs) onto a human connectome to analyze connectivity profiles.
Main Results:
- Out of 39 patients, 14 (35.9%) were responders with ≥50% pain relief at 12 months.
- Effective stimulation sites included the posterior limb of the internal capsule and sensorimotor thalamus.
- Responders showed reduced structural connectivity to sensory cortex compared to non-responders.
Conclusions:
- DBS is effective for a significant portion of patients with CPSP.
- The posterior limb of the internal capsule and sensorimotor thalamus are promising targets.
- Connectivity differences may serve as a biomarker for guiding surgical planning in future trials.

